Fast Five Quiz: Are You Prepared to Confront Metastatic Breast Cancer?

Winston W. Tan, MD; Stefania Morganti, MD


December 15, 2022

Median OS for patients with metastatic breast cancer is highly variable according to tumor subtype, ranging from ~18 months for triple-negative breast cancer to ~5 years for hormone receptor positive/HER2-negative breast cancer. Several new treatment options have recently emerged that are expected to improve median survival of newly diagnosed patients in the next decade.

For additional information, refer to the National Comprehensive Cancer Network (NCCN) Breast Cancer Clinical Practice Guidelines and the European Society for Medical Oncology (ESMO) Clinical Practice Guideline for diagnosis, staging, and treatment of patients with metastatic breast cancer.

Learn more about the optimal management of metastatic breast cancer.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.